Loading...
Efficacy and tolerability of bevacizumab in patients with severe Covid-19
On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesize that the anti-vascular endothelial growth factor (VEGF) drug bevacizumab might be beneficial for treating Covid-19 patients. From Feb 15 to April 5, 2020, we conducted a single-arm trial (NCT04275414) and re...
Saved in:
Published in: | Nat Commun |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artigo |
Language: | Inglês |
Published: |
Nature Publishing Group UK
2021
|
Subjects: | |
Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7864918/ https://ncbi.nlm.nih.gov/pubmed/33547300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-21085-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|